Impact of Collagen Triple Helix Structure on Melanoma Cell Invadopodia Formation and Matrix Degradation upon BRAF Inhibitor Treatment

Adv Healthc Mater. 2022 Apr;11(7):e2101592. doi: 10.1002/adhm.202101592. Epub 2021 Nov 25.

Abstract

A collagen-rich tumor microenvironment (TME) is associated with worse outcomes in cancer patients and contributes to drug resistance in many cancer types. In melanoma, stiff and fibrillar collagen-abundant tissue is observed after failure of therapeutic treatments with BRAF inhibitors. Increased collagen in the TME can affect properties of the extracellular matrix (ECM), including stiffness, adhesiveness, and interaction of integrins with triple helix forming nanostructures. Decoupling these biochemical and biophysical properties of the ECM can lead to a better understanding of how each of these individual properties affect melanoma cancer behavior and drug efficacy. In addition, as drug treatment can induce cancer cell phenotypic switch, cancer cell responsiveness to the TME can be dynamically changed during therapeutic treatments. To investigate cancer cell phenotype changes and the role of the cancer TME, poly(ethylene glycol) (PEG) hydrogels functionalized with collagen mimetic peptides (CMPs) is utilized, or an interpenetrating network (IPN) of type І collagen within the PEG system to culture various melanoma cell lines in the presence or absence of Vemurafenib (PLX4032) drug treatment is prepared. Additionally, the potential of using CMP functionalized PEG hydrogels, which can provide better tunability is explored, to replace the existing invadopodia assay platform based on fluorescent gelatin.

Keywords: collagen mimetic peptides; hydrogels; interpenetrating polymer networks; invadopodia; matrix metalloproteinase activity; melanoma cells; tumor microenvironments.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Collagen / chemistry
  • Extracellular Matrix / metabolism
  • Humans
  • Hydrogels / chemistry
  • Melanoma* / drug therapy
  • Melanoma* / metabolism
  • Podosomes* / metabolism
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf / metabolism
  • Tumor Microenvironment

Substances

  • Hydrogels
  • Protein Kinase Inhibitors
  • Collagen
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf